CapsoVision (NASDAQ:CV) Trading Down 3.1% – Time to Sell?

Shares of CapsoVision, Inc. (NASDAQ:CV) fell 3.1% on Thursday . The stock traded as low as $11.58 and last traded at $11.77. 12,597 shares were traded during mid-day trading, a decline of 92% from the average session volume of 163,405 shares. The stock had previously closed at $12.15.

Wall Street Analyst Weigh In

CV has been the topic of a number of recent research reports. Benchmark reaffirmed a “speculative buy” rating on shares of CapsoVision in a research note on Friday, November 14th. Weiss Ratings restated a “sell (e)” rating on shares of CapsoVision in a research note on Monday. Zacks Research raised shares of CapsoVision to a “hold” rating in a research report on Wednesday, November 5th. Finally, Roth Capital set a $7.00 price objective on CapsoVision in a report on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, CapsoVision currently has an average rating of “Moderate Buy” and an average price target of $6.00.

CapsoVision Trading Down 10.0%

The company’s 50-day moving average is $6.19.

CapsoVision (NASDAQ:CV) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). The business had revenue of $3.54 million during the quarter.

Institutional Investors Weigh In On CapsoVision

A hedge fund recently bought a new stake in CapsoVision stock. Citadel Advisors LLC purchased a new stake in CapsoVision, Inc. (NASDAQ:CV) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 23,735 shares of the company’s stock, valued at approximately $115,000. Citadel Advisors LLC owned about 0.05% of CapsoVision as of its most recent filing with the Securities and Exchange Commission.

CapsoVision Company Profile

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn’s disease.